NCT05924750View on ClinicalTrials.gov

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

August 2, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Interventions
DRUG

BL-M11D1

Administration by intravenous infusion

Trial Locations (8)

300020

RECRUITING

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

Unknown

NOT_YET_RECRUITING

Anhui Provincial Hospital, Hefei

NOT_YET_RECRUITING

Beijing Hospital, Beijing

NOT_YET_RECRUITING

Institute of Hematology, the First Hospital of Harbin, Haerbin

NOT_YET_RECRUITING

Shengjing Hospital of China Medical University, Shenyang

NOT_YET_RECRUITING

Qilu Hospital of Shandong University, Jinan

NOT_YET_RECRUITING

Shanghai Tongji Hospital, Shanghai

NOT_YET_RECRUITING

West China Hospital，Sichuan University, Chengdu

All Listed Sponsors
lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY